EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial

Mario Enrico Canonico, Jessica Parr, E Sebastian Debus iD, Mark R Nehler, Manesh R Patel iD, Sonia S Anand iD, Mark Svet, Connie N Hess iD, Warren H Capell, Joseph Ycas, Julian Chen, Michael Szarek iD und 5 weitere

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.015229 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von Mario Enrico Canonico und 16 weiteren Autor:innen. Beteiligte Einrichtung: CPC Clinical Research, Aurora, CO (M.E.C., M.R.N., C.N.H., W.H.C., J.Y., J.C., M. Szarek, S.D.B., M.P.B.). Hauptthemen laut MEDLINE: Aspirin, Endovascular Procedures, Factor Xa Inhibitors, Peripheral Arterial Disease. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with peripheral artery disease (PAD) undergoing lower extremity revascularization (LER) are at high risk of major adverse limb events (MALE) and major adverse cardiovascular events. The VOYAGER-PAD trial demonstrated that rivaroxaban 2.5 mg twice daily on top of antiplatelet therapy significantly reduced this risk. Whether the risk of major adverse cardiovascular events and MALE and the effect of rivaroxaban are consistent in patients with a history of prior LER versus those without has not been described. METHODS: VOYAGER-PAD randomized patients with symptomatic PAD undergoing LER to rivaroxaban 2.5 mg twice daily or placebo on a background of aspirin 100 mg daily. The history of prior LER was collected at baseline. The primary end point was a composite of acute limb ischemia, major amputation of a vascular cause, myocardial infarction, ischemic stroke, or cardiovascular death. The principal safety outcome was Thrombolysis in Myocardial Infarction major bleeding. RESULTS: A total of 6564 patients were enrolled with 2336 (35.5%) having a prior history of LER. Patients with a history of prior LER had a higher rate of MALE relative to those without prior LER (3-year Kaplan-Meier cumulative rates, 12.9% versus 8.0%; hazard ratio [HR], 1.58 [95% CI, 1.25–1.99]). Compared with placebo, rivaroxaban reduced the primary efficacy end point with a numerically greater relative benefit in those with (HR, 0.73 [95% CI, 0.60–0.88]) versus without prior LER (HR, 0.94 [95% CI, 0.81–1.10]; P interaction =0.036). The relative increase in Thrombolysis in Myocardial Infarction major bleeding with rivaroxaban was consistent regardless of prior LER status (prior LER: HR, 1.08 [95% CI, 0.62–1.89]; no prior LER: HR, 1.88 [95% CI, 1.09–3.25]; P interaction =0.16). CONCLUSIONS: Patients with PAD with prior LER are at particularly high risk of MALE relative to those presenting without prior LER. Rivaroxaban reduces the risk of major adverse cardiovascular events and MALE after LER for symptomatic PAD with a greater relative benefit in those with prior LER. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02504216.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinEndovascular ProceduresFactor Xa InhibitorsPeripheral Arterial DiseasePlatelet Aggregation InhibitorsRivaroxabanVascular Surgical ProceduresAgedAged, 80 and overFemaleHumansMaleMiddle AgedAmputation, SurgicalDouble-Blind MethodDrug Therapy, CombinationHemorrhageLimb SalvageLower ExtremityRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

amputation, surgicalankle brachial indexclopidogrelmyocardial infarctionperipheral artery diseaserivaroxaban

Substanzen

AspirinFactor Xa InhibitorsPlatelet Aggregation InhibitorsRivaroxaban

Autor:innen und Institutionen

  • CPC Clinical Research, Aurora, CO (M.E.C., M.R.N., C.N.H., W.H.C., J.Y., J.C., M. Szarek, S.D.B., M.P.B.).
  • Division of Cardiology, Department of Medicine (M.E.C., C.N.H., M. Szarek, S.D.B., M.P.B.), University of Colorado School of Medicine, Aurora.
  • Division of Cardiology, Heart of the Rockies, Salida, CO (J.P.).
  • Department of Vascular Medicine, Vascular Surgery-Angiology-Endovascular Therapy, University of Hamburg-Eppendorf, Germany (E.S.D.).
  • Department of Surgery (M.R.N.), University of Colorado School of Medicine, Aurora.
  • Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (M.R.P.).

ORCID-Profile: E Sebastian Debus, Manesh R Patel, Sonia S Anand, Connie N Hess, Michael Szarek, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca

Zitieren

APA

Canonico, M. E., Parr, J., Debus, E. S., Nehler, M. R., Patel, M. R., Anand, S. S., Svet, M., Hess, C. N., Capell, W. H., Ycas, J., Chen, J., Szarek, M., Muehlhofer, E., Haskell, L. P., Berkowitz, S. D., Bauersachs, R. M., & Bonaca, M. P. (2026). Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015229

Vancouver

Canonico ME, Parr J, Debus ES, Nehler MR, Patel MR, Anand SS, et al. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.015229

BibTeX
@article{Canonico2026,
  author = {Canonico, Mario Enrico and Parr, Jessica and Debus, E Sebastian and Nehler, Mark R and Patel, Manesh R and Anand, Sonia S and Svet, Mark and Hess, Connie N and Capell, Warren H and Ycas, Joseph and Chen, Julian and Szarek, Michael and Muehlhofer, Eva and Haskell, Lloyd P and Berkowitz, Scott D and Bauersachs, Rupert M and Bonaca, Marc P},
  title = {Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.015229}
}
Kostenlos starten →